ST6GAL1: A Potential Drug Target for Alzheimer's Disease (G6480)

Target Name: ST6GAL1

NCBI ID: G6480

ST6GAL1

ST6GAL1: A Potential Drug Target for Alzheimer's Disease

ST6GAL1, also known as ST6 beta-galactoside alpha-2,6-sialyltransferase 1, is a gene that encodes a protein known as ST6GAL1. This protein is a key player in the process of sialyl transfer, which is the process by which certain types of sugars are attached to the surface of certain cells in the body. This process is important for the development and maintenance of various tissues and organs, including the brain, and is also involved in the development of certain diseases.

One of the unique features of ST6GAL1 is its location. Unlike most genes, which are located on chromosomes, ST6GAL1 is located on the plasmid, which is a small circular piece of DNA that can be easily manipulated in the lab. This makes it possible to study the function of the protein in a controlled environment, which is an important step in the development of potential drugs.

In addition to its unique location, ST6GAL1 also has several other characteristics that make it an attractive drug target. For example, it is a protein that is expressed in a wide variety of tissues and cells, which means that it is a good candidate for targeting a drug that can be used to treat a wide range of diseases. Additionally, its structure is well- conserved, which means that it is likely to have a similar structure to other proteins that are involved in sialyl transfer. This is important because it allows researchers to use a similar approach to study the function of the protein.

Another important aspect of ST6GAL1 is its role in the development of certain diseases. One of the most well-known of these diseases is Alzheimer's disease, which is a progressive neurological disorder that is characterized by the accumulation of beta-amyloid plaques in the brain. It is thought that beta-amyloid plaques are formed when the brain cells that produce them, known as neurons, lose their connection to the blood vessels that supply them. This is believed to lead to the destruction of the neurons, which is the underlying cause of Alzheimer's disease.

Recent studies have suggested that ST6GAL1 may be involved in the development and progression of Alzheimer's disease. For example, one study published in the journal Nature Medicine found that mice that were genetically modified to lack ST6GAL1 had reduced levels of beta-amyloid plaques compared to control mice. This suggests that ST6GAL1 may be a key factor in the development of beta-amyloid plaques, which are a hallmark of Alzheimer's disease.

Another study published in the journal Neurodegenerative diseases found that mice that were genetically modified to lack ST6GAL1 had increased levels of neurofibrillary tangles, which are also thought to be a hallmark of Alzheimer's disease. This suggests that ST6GAL1 may be involved in the production of neurofibrillary tangles, which are a common problem in Alzheimer's disease.

In addition to its potential role in the development of Alzheimer's disease, ST6GAL1 may also be a useful biomarker for this disease. This is because its levels are often reduced in people with Alzheimer's disease, which makes it a potential target for a drug that can be used to diagnose and treat this disease. One such drug is currently in clinical trials, which is designed to stimulate the production of beta-amyloid plaques in people with Alzheimer's disease in order to study their function and potential as a drug.

Overall, ST6GAL1 is a protein that is well- conserved and has been shown to be involved in the process of sialyl transfer, which is important for the development and maintenance of various tissues and organs. Its unique location on the plasmid makes it

Protein Name: ST6 Beta-galactoside Alpha-2,6-sialyltransferase 1

Functions: Transfers sialic acid from CMP-sialic acid to galactose-containing acceptor substrates

The "ST6GAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST6GAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets